Intervention
Cabazitaxel (XRP6258)
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 3 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
3 shownCabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate CancerNCT01308567 · 2011-05-05
COMPLETEDCabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate CancerNCT01308580 · 2011-04-01
COMPLETEDDose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate CancerNCT01324583 · 2011-01-01
COMPLETEDCommon conditions
Leading sponsors
Trial status mix
COMPLETED3
Phase mix
PHASE32
PHASE11
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.